Inogen Inc
INGN- Exchange
- Nasdaq
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- SEC CIK
- 0001294133
No open-market purchases or sales by Inogen Inc insiders were filed in the last 90 days; 129 institutions reported holding it in 13F filings for Q2 2026, worth $124.3M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $22.7M (6.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Feb 27, 2024 | Jan 10, 2023 | Jan 10, 2022 |
| Revenue | $348.7M | $335.7M | $315.7M | $377.2M | $358.0M |
| Cost of revenue | $194.4M | $181.0M | $189.0M | $223.7M | $181.5M |
| Gross profit | $154.3M | $154.7M | $126.7M | $153.5M | $176.5M |
| Operating expenses | $184.5M | $197.3M | $236.1M | $238.8M | $167.2M |
| Research and development | $19.4M | $21.6M | $20.8M | $21.9M | $16.6M |
| Selling, general and administrative | $67.4M | $72.6M | $75.3M | $43.9M | $37.9M |
| Operating income | -$30.2M | -$42.5M | -$109.4M | -$85.2M | $9.24M |
| Income tax | -$632.0K | -$588.0K | $105.0K | $504.0K | $15.0M |
| Net income | -$22.7M | -$35.9M | -$102.4M | -$83.8M | -$6.33M |
| EPS, basic | $-0.86 | $-1.52 | $-4.42 | $-3.67 | $-0.28 |
| EPS, diluted | $-0.86 | $-1.52 | $-4.42 | $-3.67 | $-0.28 |
| Weighted shares, basic | 26.6M | 23.7M | 23.2M | 22.9M | 22.5M |
| Weighted shares, diluted | 26.6M | 23.7M | 23.2M | 22.9M | 22.5M |
| Margins and growth | |||||
| Gross margin | 44.2% | 46.1% | 40.1% | 40.7% | 49.3% |
| Operating margin | -8.7% | -12.7% | -34.7% | -22.6% | 2.6% |
| Net margin | -6.5% | -10.7% | -32.5% | -22.2% | -1.8% |
| Revenue growth, year over year | +3.9% | +6.4% | −16.3% | +5.4% | +16.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Feb 27, 2024 | Jan 10, 2023 | Jan 10, 2022 |
| Cash and equivalents | $103.7M | $113.8M | $125.5M | $187.0M | $235.5M |
| Accounts receivable | $38.9M | $29.6M | $42.2M | $62.7M | $24.5M |
| Inventory | $26.0M | $24.8M | $21.8M | $34.1M | $31.9M |
| Total current assets | $198.3M | $185.5M | $207.1M | $304.6M | $329.2M |
| Property, plant and equipment | $36.4M | $44.4M | $50.3M | $43.3M | $38.9M |
| Goodwill | $10.7M | $9.46M | $10.1M | $32.9M | $33.0M |
| Intangible assets | $30.8M | $30.5M | $34.6M | $177.0K | $60.1M |
| Total assets | $298.6M | $296.2M | $326.2M | $405.0M | $489.5M |
| Accounts payable | $20.3M | $16.6M | $13.5M | $18.2M | $10.3M |
| Total current liabilities | $63.5M | $76.7M | $72.5M | $65.3M | $61.5M |
| Total liabilities | $106.4M | $122.3M | $121.4M | $107.6M | $119.3M |
| Shareholders' equity | $192.2M | $173.9M | $204.8M | $297.4M | $370.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Feb 27, 2024 | Jan 10, 2023 | Jan 10, 2022 |
| Operating cash flow | -$11.2M | $5.91M | -$3.23M | -$37.5M | $23.6M |
| Capital expenditures | $2.52M | $3.36M | $5.22M | $3.34M | $5.48M |
| Free cash flow | -$13.7M | $2.55M | -$8.45M | -$40.9M | $18.2M |
| Depreciation and amortization | $20.7M | $21.0M | $18.2M | $23.5M | $21.6M |
| Stock-based compensation | $8.01M | $7.40M | $7.43M | $12.3M | $10.9M |
| Investing cash flow | -$26.2M | -$14.0M | -$59.3M | -$10.9M | -$14.6M |
| Financing cash flow | $24.2M | $265.0K | $960.0K | $380.0K | $15.0M |
| Net change in cash | -$12.4M | -$8.08M | -$61.5M | -$48.5M | $23.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 2.3% | 2.2% | 2.4% | 3.3% | 3.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.